Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 17/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107197 | 0.93 | GABRA5 (0.50) | GABRA5 | |
| SCHEMBL2672278 | 0.85 | SMPD1 (0.43) | GABRA5GABRA1 | |
| SCHEMBL285756 | 0.84 | GABRA5 (0.70) | GABRA5GABRA1ITGA5 | |
| SCHEMBL285878 | 0.82 | GABRA5 (0.67) | GABRA5GABRA1 | |
| SCHEMBL285682 | 0.82 | GABRA5 (0.68) | GABRA5GABRA1 | |
| SCHEMBL285820 | 0.82 | GABRA5 (0.68) | GABRA5ITGA5 | |
| SCHEMBL286297 | 0.82 | GABRA5 (0.37) | GABRA5GABRA1ITGA5 | |
| SCHEMBL285768 | 0.82 | GABRA5 (0.69) | GABRA5GABRA1ITGA5 | |
| SCHEMBL285417 | 0.82 | GABRA5 (0.69) | GABRA5GABRA1ITGA5 | |
| SCHEMBL107842 | 0.82 | GABRA5 (0.52) | GABRA5GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424863-B1 | ISOXAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-09-18 | — | — | EP | claimed |
| US-8227461-B2 | Isoxazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | claimed |
| EP-2424863-A1 | ISOXAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-07 | — | — | EP | claimed |
| US-20100280019-A1 | ISOXAZOLES | JAKOB-ROETNE ROLAND | 2010-11-04 | — | — | US | claimed |
| US-20100280020-A1 | ISOXAZOLES | ROCHE PALO ALTO LLC | 2010-11-04 | — | — | US | claimed |
| WO-2010125042-A1 | ISOXAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-04 | — | — | WO | claimed |
| EP-2424863-B1 | ISOXAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-09-18 | — | — | EP | disclosed |
| EP-2424863-B1 | ISOXAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8227461-B2 | Isoxazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227461-B2 | Isoxazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227461-B2 | Isoxazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2424863-A1 | ISOXAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125042-A1 | ISOXAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280019-A1 | ISOXAZOLES | JAKOB-ROETNE ROLAND | 2010-11-04 | — | — | US | disclosed |
| US-20100280019-A1 | ISOXAZOLES | JAKOB-ROETNE ROLAND | 2010-11-04 | — | — | US | disclosed |
| US-20100280019-A1 | ISOXAZOLES | JAKOB-ROETNE ROLAND | 2010-11-04 | — | — | US | disclosed |
| US-20100280020-A1 | ISOXAZOLES | ROCHE PALO ALTO LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280020-A1 | ISOXAZOLES | ROCHE PALO ALTO LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280020-A1 | ISOXAZOLES | ROCHE PALO ALTO LLC | 2010-11-04 | — | — | US | disclosed |
| WO-2010125042-A1 | ISOXAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280020-A1 | ISOXAZOLES | GABRA5, GABRA1, GABRA3 | GABRA5 1/4885GABRA1 2/4885ITGA5 166/4885 |
| US-20100280019-A1 | ISOXAZOLES | GABRA5, GABRA1, GABRA3 | GABRA5 1/4885GABRA1 2/4885ITGA5 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.